- Home
- AEON vs SCNX Comparison
AEON vs SCNX Comparison
Compare AEON & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | SCNX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.5M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AEON | SCNX |
|---|---|---|
| Price | $0.19 | $2.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $7.20 | $1.50 |
| AVG Volume (30 Days) | ★ 981.2K | 679.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.20 | $0.24 |
| 52 Week High | $1.45 | $2.60 |
Technical Indicators
Market Signals| Indicator | AEON | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 20.40 | 63.61 |
| Support Level | N/A | $0.37 |
| Resistance Level | $0.34 | $0.48 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 13.31 | 89.67 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.